Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CGNX vs BMI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGNX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–2 Matrix Metrics)
CGNX Overall Winner
6-Pillar Tally: CGNX 6 – 0 BMI
Matrix Metrics: CGNX 7 – 2 BMI
As of Nov 16, 2026, Cognex Corp (CGNX) is the stronger overall head-to-head candidate over Badger Meter, Inc. (BMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGNX carries a Unified Composite Score of 59.5/100 (HOLD) at $48.06 (24.7x Forward P/E, 25.0% operating margin), whereas BMI carries 46.0/100 (HOLD) at $160.76 (31.0x Forward P/E, 18.8% operating margin).
- Technical & Structure Timing Caution: CGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.9); meanwhile BMI trades in a Markup technical trend (SURGE options phase, RSI 62.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CGNX vs BMI
CGNX
Head-to-Head Winner
Cognex Corp
$48.06
-3.9% 1D
Market Cap
$8.5B
TTM Revenue
$1.13B
Forward P/E
24.7x
Beta / 30D Vol
2.19β · 65% Vol
Unified Composite Score
59.5
HOLD
Tech 45.0
Fund 54.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
BMI
Badger Meter, Inc.
$160.76
+3.9% 1D
Market Cap
$4.5B
TTM Revenue
$881M
Forward P/E
31.0x
Beta / 30D Vol
0.49β · 67% Vol
Unified Composite Score
46.0
HOLD
Tech 32.0
Fund 47.0
Flow 56.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (CGNX 6 – 0 BMI)
1. Valuation Multiples
CGNX
Forward P/E
24.7x
31.0x
Trailing P/E
35.5x
35.5x
PEG Ratio
2.71x
3.68x
EV / Revenue
7.0x
5.1x
2. Growth & Scale
CGNX
Revenue Growth (YoY)
+13.2%
+0.1%
Earnings Growth (YoY)
+400.0%
+4.2%
TTM Revenue (USD)
$1.13B
$881M
Market Cap
$8.5B
$4.5B
3. Profitability & Quality
CGNX
Gross Margin
69.7%
41.6%
Operating Margin
25.0%
18.8%
Net Profit Margin
21.5%
14.4%
Return on Equity (ROE)
15.1%
18.7%
4. Balance Sheet & Cash Flow
CGNX
Cash Generation (TTM)
$286M
$142M
Cash Flow Margin
25.4%
16.2%
Net Cash / Leverage
$624M Net Cash
$22.80 Book/Sh · 18.7% ROE
Dividend Yield
0.66%
1.03%
5. Options & Positioning
CGNX
Options Structure Phase
BREAKDOWN
SURGE
Current IV / %ile
53.5% (16th %ile)
39.0% (7th %ile)
Put/Call OI Skew
1.96x (Put-Skewed)
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
CGNX
OpEx & R&D Intensity
44.7% of Rev ($503M)
22.8% of Rev ($201M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Scale & Operating Efficiency Moat
Supply-Chain Role
Scientific & Technical Instruments Operator
Scientific & Technical Instruments Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CGNX (7) vs BMI (2)| Institutional Metric | CGNX | BMI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $8.5B | $4.5B | CGNX | |
| Trailing P/E Ratio | 35.5x | 35.5x | Tie | |
| Forward P/E Ratio | 24.7x | 31.0x | CGNX | |
| Revenue Growth (YoY) | +13.2% | +0.1% | CGNX | |
| Operating Margin (TTM) | 25.0% | 18.8% | CGNX | |
| Net Profit Margin | 21.5% | 14.4% | CGNX | |
| Return on Equity (ROE) | 15.1% | 18.7% | BMI | |
| 52-Week Range Position | 35% ($35–$73) | 65% ($112–$187) | BMI | |
| Beta / 30D Volatility | 2.19β · 65% Vol | 0.49β · 67% Vol | CGNX | |
| Unified Institutional Score | 59.5 / 100 (HOLD) | 46.0 / 100 (HOLD) | CGNX | |
| Trailing 12M Revenue (USD) | $1.13B | $881M | Scale | |
| Gross Profit Margin (TTM) | 69.7% | 41.6% | Quality | |
| PEG Ratio & EV / Revenue | 2.71x PEG · 7.0x EV/Rev | 3.68x PEG · 5.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $286M ($624M Net Cash) | $142M ($22.80 Book/Sh · 18.7% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BMI +38.08 pp
3M Horizon
BMI +51.91 pp
6M Horizon
BMI +57.51 pp
1Y Horizon
CGNX +39.3 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGNX Revenue | BMI Revenue | CGNX Op. Margin | BMI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $810M | $430M | 27.4% | 13.1% | CGNX |
| FY2019 | $730M | $420M | 19.7% | 14.6% | CGNX |
| FY2020 | $810M | $430M | 21.0% | 15.3% | CGNX |
| FY2021 | $1.04B | $510M | 30.4% | 15.6% | CGNX |
| FY2022 | $1.01B | $570M | 24.5% | 15.4% | CGNX |
| FY2023 | $840M | $700M | 15.6% | 16.8% | BMI |
| FY2024 | $910M | $830M | 12.6% | 19.1% | BMI |
| FY2025 | $990M | $920M | 16.3% | 20.0% | BMI |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CGNX
BREAKDOWN
Current IV
53.5%
IV Percentile
16th %ile
Put/Call OI Skew
1.96x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact CGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BMI
SURGE
Current IV
39.0%
IV Percentile
7th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact BMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CGNX Moat Profile
Scale & Operating Efficiency Moat
Scientific & Technical Instruments Operator
OpEx & R&D Reinvestment
44.7% of Rev ($503M)
90D Engineering Disclosures
0 Published
BMI Moat Profile
Scale & Operating Efficiency Moat
Scientific & Technical Instruments Operator
OpEx & R&D Reinvestment
22.8% of Rev ($201M)
90D Engineering Disclosures
0 Published
Investor FAQ CGNX vs BMI Key Questions & Quantitative Answers
As of Nov 16, 2026, Cognex Corp (CGNX) is the stronger overall head-to-head candidate over Badger Meter, Inc. (BMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGNX carries a Unified Composite Score of 59.5/100 (HOLD) at $48.06 (24.7x Forward P/E, 25.0% operating margin), whereas BMI carries 46.0/100 (HOLD) at $160.76 (31.0x Forward P/E, 18.8% operating margin). Technical & Structure Timing Caution: CGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.9); meanwhile BMI trades in a Markup technical trend (SURGE options phase, RSI 62.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGNX leads the Growth & Scale pillar: CGNX posts +13.2% YoY revenue growth and +400.0% YoY earnings growth on $1.13B TTM revenue (69.7% gross margin, 25.0% operating margin), compared with BMI at +0.1% YoY revenue growth and +4.2% YoY earnings growth on $881M TTM revenue (41.6% gross margin, 18.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGNX cumulative revenue shifted +22.2% while BMI shifted +114.0%. In operating R&D and SG&A reinvestment, CGNX deploys 44.7% of Rev ($503M) (0 90-day corporate R&D disclosures) versus 22.8% of Rev ($201M) (0 disclosures) for BMI.
CGNX screens cheaper on headline valuation multiples. CGNX trades at 24.7x Forward P/E, 35.5x Trailing P/E, 2.71x PEG, and 7.0x EV/Revenue (25.4% FCF margin), whereas BMI trades at 31.0x Forward P/E, 35.5x Trailing P/E, 3.68x PEG, and 5.1x EV/Revenue (16.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGNX (15.1% ROE) versus BMI (18.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CGNX carries 53.5% implied volatility (16th %ile, Compressed (<25th %ile)), a 1.96x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.19β · 65% Vol realized risk). By comparison, BMI carries 39.0% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.49β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BMI vs CGNX · Reverse Pair
CGNX vs ZBRA
· Sector Peer
CGNX vs ROK
· Sector Peer
CGNX vs IPGP
· Sector Peer
BMI vs FELE
· Sector Peer
BMI vs BRC
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem